Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases
By Dr. Matthew Watson
COPENHAGEN, Denmark, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that it has appointed Mark A. Bach, M.D., Ph.D., as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases.
See the article here:
Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases
Harpoon Therapeutics Appoints Omer Siddiqui as VP Development Operations and Project Management
By Dr. Matthew Watson
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Omer Siddiqui as Vice President, Development Operations and Project Management. Mr. Siddiqui joins Harpoon most recently from Alector, where he served as Vice President, Head of Development Operations.
See original here:
Harpoon Therapeutics Appoints Omer Siddiqui as VP Development Operations and Project Management
Nu-Med Plus Announces Filing of U.S. Provisional Patent Application for Nitric Oxide in Aqueous Solution for Wound Care Treatment
By Dr. Matthew Watson
SALT LAKE CITY, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc. (OTCQB: NUMD), a medical device company which investigates and develops applications and devices for nitric oxide in the medical field, today announced that the Company has filed a U.S. provisional patent application entitled, “Kinetically Controlled Method of In Situ Generation of Nitric Oxide in an Aqueous Solution.” The patent broadly covers the kinetically controlled generation of nitric oxide in an aqueous solution to provide a time dose curve that can be effectively used for treatment of various dermal wounds.
Go here to read the rest:
Nu-Med Plus Announces Filing of U.S. Provisional Patent Application for Nitric Oxide in Aqueous Solution for Wound Care Treatment
Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting
By Dr. Matthew Watson
CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Today, Biogen Inc. (Nasdaq: BIIB) announced positive data from the 24-week systemic lupus erythematosus (SLE) portion of the Phase 2 LILAC study (part A) demonstrating that BIIB059 (anti-BDCA2) was associated with a statistically significant reduction in total active joint count. The study evaluated the efficacy and safety of BIIB059, a humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) expressed exclusively on plasmacytoid dendritic cells. These data, along with the previously reported findings from the cutaneous lupus erythematosus (CLE) portion of the LILAC study, will be presented at the American College of Rheumatology’s ACR Convergence 2020, being held virtually from November 5-9, 2020.
GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress
By Dr. Matthew Watson
- Total revenue increased 51 percent to $137.1 million – - Epidiolex for seizures associated with TSC launched in the U.S. -- Nabiximols Phase 3 program in MS spasticity now recruiting -- Conference call today at 8:30 a.m. EST -
Read more:
GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress
XOMA Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance
By Dr. Matthew Watson
EMERYVILLE, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the rights to future milestone and royalty revenue due to Bioasis Technologies Inc. (TSXV:BTI.V; OTCQB:BIOAF), associated with the advancement of the enzymes being investigated as potential treatments for four different lysosomal storage disorders (LSD) under Bioasis’ strategic alliance with Chiesi Group.
See original here:
XOMA Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance
Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
By Dr. Matthew Watson
MALVERN, Pa., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Tuesday, November 10, 2020, at 11:45 a.m. ET.
More:
Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
Catalyst Biosciences to Present at Stifel 2020 Virtual Healthcare Conference
By Dr. Matthew Watson
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Nassim Usman, Ph.D., president and chief executive officer, and Clinton Musil, chief financial officer, of Catalyst Biosciences will present at the Stifel 2020 Virtual Healthcare Conference taking place on November 16-18, 2020. Details for the company presentation are as follows:
See the article here:
Catalyst Biosciences to Present at Stifel 2020 Virtual Healthcare Conference
Motus GI and NYU Langone Health Partner to Improve its Inpatient Colonoscopy Management
By Dr. Matthew Watson
FORT LAUDERDALE, Fla., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions to help improve clinical outcomes, is launching a new clinical protocol with NYU Langone Health to incorporate the Company’s Pure-Vu® GEN2 System (Pure-Vu) with the intention to improve the management of its inpatient colonoscopies.
Read more:
Motus GI and NYU Langone Health Partner to Improve its Inpatient Colonoscopy Management
Novavax to Host Conference Call to Discuss Third Quarter Financial and Operating Results on November 9, 2020
By Dr. Matthew Watson
GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2020 financial and operating results following the close of U.S. financial markets on Monday, November 9, 2020.
Read the original here:
Novavax to Host Conference Call to Discuss Third Quarter Financial and Operating Results on November 9, 2020
Altimmune to Announce Third Quarter 2020 Financial Results on November 10
By Dr. Matthew Watson
GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020.
Read more:
Altimmune to Announce Third Quarter 2020 Financial Results on November 10
Allena Pharmaceuticals to Participate Virtually in Upcoming Investor Conferences in November
By Dr. Matthew Watson
NEWTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in three upcoming investor conferences in November:
Continue reading here:
Allena Pharmaceuticals to Participate Virtually in Upcoming Investor Conferences in November
TRACON to Report Third Quarter 2020 Financial Results and Company Highlights on November 10, 2020
By Dr. Matthew Watson
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its third quarter 2020 financial and operating results after the close of U.S. financial markets on Tuesday, November 10, 2020. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
Read more from the original source:
TRACON to Report Third Quarter 2020 Financial Results and Company Highlights on November 10, 2020
Abcam plc: Consultation on 2020 LTIP Awards
By Dr. Matthew Watson
CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following consultation with shareholders on the Group’s overall LTIP structure and performance framework, including proposed changes for this year’s awards, it has determined to retain the existing LTIP metrics and targets contained in Abcam’s current Remuneration Policy, as approved by shareholders in 2018.
Read the original here:
Abcam plc: Consultation on 2020 LTIP Awards
Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
By Dr. Matthew Watson
MONMOUTH JUNCTION, N.J., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a?late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the completion of patient enrollment for its planned open-label safety study evaluating ONS-5010/LYTENAVA™ (NORSE THREE). Patient enrollment for the study was completed in less than one month, significantly ahead of the planned four-month enrollment schedule.
Read more here:
Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Abcam plc: Annual Report, Impact Report and Notice of AGM
By Dr. Matthew Watson
CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following release on 14 September 2020 of its final results for the year ended 30 June 2020, the Abcam plc Annual Report and Accounts 2020 (the “Annual Report”) have been published today and are available on the Abcam plc website at www.abcamplc.com.
Go here to read the rest:
Abcam plc: Annual Report, Impact Report and Notice of AGM
Ocuphire Pharma to Host Key Opinion Leader Event on Nyxol® and APX3330
By Dr. Matthew Watson
Live Webinar Featuring 3 KOLs Focused on Front and Back of the Eye Conditions and Opportunities for New Treatments on Monday, November 9, at 10:00am ET Live Webinar Featuring 3 KOLs Focused on Front and Back of the Eye Conditions and Opportunities for New Treatments on Monday, November 9, at 10:00am ET
See the rest here:
Ocuphire Pharma to Host Key Opinion Leader Event on Nyxol® and APX3330
Progenity to Report Third Quarter 2020 Financial Results and Provide Corporate Update
By Dr. Matthew Watson
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report third quarter 2020 financial results on Monday, November 9, 2020 after the close of financial markets. Progenity’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
See the original post here:
Progenity to Report Third Quarter 2020 Financial Results and Provide Corporate Update
Silencil Reviews – Groundbreaking New Report on Silencil For Tinnitus
By Dr. Matthew Watson
To Read More: Silencil Reviews – Groundbreaking New Report on Silencil For TinnitusBellicum Announces Interim BPX-601 Data and Corporate Restructuring
By Dr. Matthew Watson
HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data from its BPX-601 dose-escalation clinical trial in patients with relapsed/refractory metastatic pancreatic cancer. Findings from the first four patients treated with BPX-601 followed by repeat rimiducid dosing showed evidence of rimiducid-mediated CAR-T cell activation. Clinically meaningful efficacy as measured by RECIST criteria was not observed.
Read the original here:
Bellicum Announces Interim BPX-601 Data and Corporate Restructuring